Key result
Longer DAPT linked to ~34% lower MACCE risk after coronary bifurcation stenting.
Why the study?
The relationship between DAPT duration, treatment of coronary bifurcation lesions, and clinical outcomes has been poorly investigated in real-world registries.
Cohort (n=5,036)
Yes
Hazard Ratio: 0.66 (95% CI 0.58–0.77)
Absolute Event Rate: 14% vs 10%
p-value: p=<0.001
Short DAPT linked to higher MACCE after bifurcation stenting; leaves open whether prolonged regimens improve outcomes in this subgroup.
Background Duration of Dual Antiplatelet Therapy (DAPT) following Acute Coronary Syndromes (ACS) or Stable Coronary Artery Disease (SCAD) treated with coronary stenting is still debated. Although current guidelines consider several “clinical” criteria to decide for short DAPT (<6 months), standard DAPT (12 months) and prolonged DAPT (>12 months), the relationship between DAPT duration, treatment of bifurcations and its impact on clinical outcome has been poorly investigated in real world registries. Purpose We evaluated the impact of DAPT duration on clinical outcomes in consecutive all-comers patients treated with stenting of coronary artery bifurcation lesions included in the Euro Bifurcation Club -P2BiTO - registry. Methods Data on 5036 consecutive patients who underwent PCI on coronary bifurcation at 17 major coronary intervention centres between January 2012 and December 2014 were collected. The primary endpoint of the study was the cumulative occurrence of Major Adverse Cardiac Events (MACCE), defined as a composite of overall-death death, non-fatal myocardial infarction (MI), target vessel revascularization (TVR) and stroke during the follow-up; the secondary endpoints were the single occurrence of any of the above mentioned events. Results Data on DAPT duration was available for 3992 patients (79%). Patients were divided into 3 groups: Group 1) DAPT <6-months (n=720); Group 2) DAPT >6-months but <12-month (n=1602); Group 3) DAPT >12-months (n=1670). Follow up was completed in 3935 (98%) patients with a median of 20 months (C.I.=12–28). At 24 months after the index procedure, MACCE occurred more frequently in the DAPT <6-month group (Group 1) as compared with both Group 2 and 3 (respectively, 102 (14%) versus 154 (10%) and 164 (10%), HR: 0.72 (0.64–0.82), p<0.001). This difference remains after adjustment for clinical and angiographic characteristics (HR: 0.66 (0.58–0.77), p<0.001). On the contrary, no significant difference was found between Group 2 and Group 3 patients. At the Kaplan-Meier analysis (Figure 1), freedom from MACCE survival was significantly lower in patients receiving DAPT for less than 6 months (Log-Rank: 29.5, p<0.001). Figure 1. Kaplan-Meier curves Conclusions In the P2BiTO registry, short DAPT duration of less than 6 months was associated with a significantly higher risk of MACCE compared to longer DAPT in a real-world registry of patients treated for coronary artery bifurcation stenosis.
No takes yet. Share an insight, caveat, or question.
Serafino et al. (2019) conducted a cohort in Coronary artery bifurcation lesions (n=5,036). Short Dual Antiplatelet Therapy (DAPT <6 months) vs. Longer DAPT (>6 months) was evaluated on Major Adverse Cardiac Events (MACCE), defined as a composite of overall death, non-fatal myocardial infarction, target vessel revascularization, and stroke (HR 0.66, 95% CI 0.58-0.77, p=<0.001). Short DAPT (<6 months) following coronary bifurcation stenting was associated with a significantly higher risk of MACCE compared to longer DAPT durations (14% vs 10%; adjusted HR 0.66; 95% CI 0.58-0.77; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: